Related Experiment Video
Updated: Jul 6, 2026
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study
Henrik Toft Sørensen1, Steffen Christensen, Frank Mehnert
1Department of Clinical Epidemiology, Aarhus University Hospital, 8000 Aarhus C, Denmark. hts@dce.au.dk
Objective:
To assess the association between atrial fibrillation and flutter and use of bisphosphonates for osteoporosis among women.
Design:
Population based case-control study, using medical databases from Denmark.
Setting:
Northern Denmark.
Participants:
13 586 patients with atrial fibrillation and flutter and 68 054 population controls, all with complete hospital and prescription history.
Main Outcome Measure:
Adjusted relative risk of atrial fibrillation and flutter.
Results:
435 cases (3.2%) and 1958 population controls (2.9%) were current users of bisphosphonates for osteoporosis. Etidronate and alendronate were used with almost the same frequency among cases and controls. The adjusted relative risk of current use of bisphosphonates compared with non-use was 0.95 (95% confidence interval 0.84 to 1.07). New users had a relative risk of 0.75 (95% confidence interval 0.49 to 1.16), broadly similar to the estimate for continuing users (relative risk 0.96, 95% confidence interval 0.85 to 1.09). The relative risk estimates were independent of number of prescriptions and the position of the atrial fibrillation and flutter diagnosis in the discharge record, and were similar for inpatients and outpatients.
Conclusion:
No evidence was found that use of bisphosphonates increases the risk of atrial fibrillation and flutter.
Related Concept Videos
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...